Modalities for reducing interleukin 1 activity in disease
- 1 May 1993
- journal article
- review article
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 14 (5) , 155-159
- https://doi.org/10.1016/0165-6147(93)90200-4
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AI 15614)
This publication has 26 references indexed in Scilit:
- Natural and recombinant interleukin 1 receptor antagonist does not inhibit human T-cell proliferation induced by mitogens, soluble antigens or allogeneic determinantsCytokine, 1992
- Production of interleukin-1-receptor antagonist during experimental endotoxaemiaThe Lancet, 1991
- Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitroImmunology Today, 1991
- Regulation of Alloreactivity in Vivo by a Soluble Form of the Interleukin-1 ReceptorScience, 1990
- Differential activity of interleukin 1α and interleukin 1β in the stimulation of the immune response in vivoEuropean Journal of Immunology, 1990
- The Effect of Dietary Supplementation with n—3 Polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear CellsNew England Journal of Medicine, 1989
- Interleukin 1-dependent paracrine granulopoiesis in chronic granulocytic leukemia of the juvenile type.Journal of Clinical Investigation, 1988
- Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.Journal of Clinical Investigation, 1988
- Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids.Journal of Clinical Investigation, 1988
- Prostacyclin Synthesis Induced in Vascular Cells by Interleukin-1Science, 1985